You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases
Free

 

Online download statistics by month:

Online download statistics by month: November 2022 to August 2024

AbstractFullPdf
Nov 2022374022
Dec 202292011
Jan 20238206
Feb 20239607
Mar 2023100012
Apr 202310608
May 20236405
Jun 20238806
Jul 202384023
Aug 20236006
Sep 20235607
Oct 20235003
Nov 20236602
Dec 20235004
Jan 20245405
Feb 20241801
Mar 20244809
Apr 20245408
May 20247008
Jun 20248406
Jul 20243807
Aug 202472010
Total18060176